Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 224

1.

Characterizing intestinal strictures of Crohn's disease in vivo by endoscopic photoacoustic imaging.

Lei H, Johnson LA, Eaton KA, Liu S, Ni J, Wang X, Higgins PDR, Xu G.

Biomed Opt Express. 2019 Apr 24;10(5):2542-2555. doi: 10.1364/BOE.10.002542. eCollection 2019 May 1.

2.

Performance of a Deep Learning Model vs Human Reviewers in Grading Endoscopic Disease Severity of Patients With Ulcerative Colitis.

Stidham RW, Liu W, Bishu S, Rice MD, Higgins PDR, Zhu J, Nallamothu BK, Waljee AK.

JAMA Netw Open. 2019 May 3;2(5):e193963. doi: 10.1001/jamanetworkopen.2019.3963.

3.

Development and Validation of Machine Learning Models in Prediction of Remission in Patients With Moderate to Severe Crohn Disease.

Waljee AK, Wallace BI, Cohen-Mekelburg S, Liu Y, Liu B, Sauder K, Stidham RW, Zhu J, Higgins PDR.

JAMA Netw Open. 2019 May 3;2(5):e193721. doi: 10.1001/jamanetworkopen.2019.3721.

4.

Citrobacter rodentium induces tissue-resident memory CD4+ T-cells.

Bishu S, Hou G, El Zaatari M, Bishu SR, Popke D, Zhang M, Grasberger H, Zou W, Stidham RW, Higgins PDR, Spence JR, Kamada N, Kao JY.

Infect Immun. 2019 May 6. pii: IAI.00295-19. doi: 10.1128/IAI.00295-19. [Epub ahead of print]

PMID:
31061145
5.

Serum Protein Biomarkers of Fibrosis Aid in Risk Stratification of Future Stricturing Complications in Pediatric Crohn's Disease.

Wu J, Lubman DM, Kugathasan S, Denson LA, Hyams JS, Dubinsky MC, Griffiths AM, Baldassano RN, Noe JD, Rabizadeh S, Gulati AS, Rosh JR, Crandall WV, Higgins PDR, Stidham RW.

Am J Gastroenterol. 2019 May;114(5):777-785. doi: 10.14309/ajg.0000000000000237.

PMID:
31058681
6.

Efficacy of Fecal Microbiota Transplantation in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis.

Xu D, Chen VL, Steiner CA, Berinstein JA, Eswaran S, Waljee AK, Higgins PDR, Owyang C.

Am J Gastroenterol. 2019 Mar 20. doi: 10.14309/ajg.0000000000000198. [Epub ahead of print]

PMID:
30908299
7.

The Impact of Raising the Bar for Clinical Trials in Ulcerative Colitis.

Sands BE, Cheifetz AS, Nduaka CI, Quirk D, Wang W, Maller E, Friedman GS, Su C, Higgins PDR.

J Crohns Colitis. 2019 Feb 14. pii: jjz038. doi: 10.1093/ecco-jcc/jjz038. [Epub ahead of print]

PMID:
30879034
8.

Flagellin-mediated activation of IL-33-ST2 signaling by a pathobiont promotes intestinal fibrosis.

Imai J, Kitamoto S, Sugihara K, Nagao-Kitamoto H, Hayashi A, Morhardt TL, Kuffa P, Higgins PDR, Barnich N, Kamada N.

Mucosal Immunol. 2019 May;12(3):632-643. doi: 10.1038/s41385-019-0138-4. Epub 2019 Feb 11.

PMID:
30742042
9.

CD4+ tissue-resident memory T-cells expand and are a major source of mucosal tumor necrosis factor α in active Crohn's Disease.

Bishu S, El Zaatari M, Hayashi A, Hou G, Bowers N, Kinnucan J, Manoogian B, Muza-Moons MM, Zhang M, Grasberger H, Bourque C, Zou W, Higgins PDR, Spence JR, Stidham RW, Kamada N, Kao JY.

J Crohns Colitis. 2019 Feb 4. doi: 10.1093/ecco-jcc/jjz010. [Epub ahead of print]

PMID:
30715262
10.

Long-term safety and tolerability of oral tofacitinib in patients with Crohn's disease: results from a phase 2, open-label, 48-week extension study.

Panés J, D'Haens GR, Higgins PDR, Mele L, Moscariello M, Chan G, Wang W, Niezychowski W, Su C, Maller E.

Aliment Pharmacol Ther. 2019 Feb;49(3):265-276. doi: 10.1111/apt.15072.

PMID:
30663107
11.

Adalimumab persistence for inflammatory bowel disease in veteran and insured cohorts.

Govani SM, Lipson R, Noureldin M, Wiitala W, Higgins PDR, Saini SD, Pugh JA, Velligan DI, Stidham RW, Waljee AK.

Am J Manag Care. 2018 Dec 1;24(12):e374-e379.

12.

The Development of Patient-Reported Outcome Measures in Inflammatory Bowel Disease.

Higgins PDR.

Gastroenterol Hepatol (N Y). 2018 Nov;14(11):658-661. No abstract available.

13.

Efficacy of Induction Therapy With High-Intensity Tofacitinib in 4 Patients With Acute Severe Ulcerative Colitis.

Berinstein JA, Steiner CA, Regal RE, Allen JI, Kinnucan JAR, Stidham RW, Waljee AK, Bishu S, Aldrich LB, Higgins PDR.

Clin Gastroenterol Hepatol. 2019 Apr;17(5):988-990.e1. doi: 10.1016/j.cgh.2018.11.022. Epub 2018 Nov 17.

PMID:
30458248
14.

Incidence and predictors of new persistent opioid use following inflammatory bowel disease flares treated with oral corticosteroids.

Noureldin M, Higgins PDR, Govani SM, Cohen-Mekelburg S, Kenney BC, Stidham RW, Waljee JF, Waljee AK.

Aliment Pharmacol Ther. 2019 Jan;49(1):74-83. doi: 10.1111/apt.15023. Epub 2018 Nov 14.

PMID:
30430615
15.

A Method for Cryogenic Preservation of Human Biopsy Specimens and Subsequent Organoid Culture.

Tsai YH, Czerwinski M, Wu A, Dame MK, Attili D, Hill E, Colacino JA, Nowacki LM, Shroyer NF, Higgins PDR, Kao JY, Spence JR.

Cell Mol Gastroenterol Hepatol. 2018 May 30;6(2):218-222.e7. doi: 10.1016/j.jcmgh.2018.04.008. eCollection 2018. No abstract available.

16.

5-ASA to sulfasalazine drug switch program in patients with ulcerative colitis.

Goldsmith JR, Waljee AK, George T, Brown A, Choe HM, Noureldin M, Bernstein SJ, Higgins PDR.

Am J Manag Care. 2018 Jul;24(8 Spec No.):SP303-SP308.

17.

Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis.

Hanauer S, Panaccione R, Danese S, Cheifetz A, Reinisch W, Higgins PDR, Woodworth DA, Zhang H, Friedman GS, Lawendy N, Quirk D, Nduaka CI, Su C.

Clin Gastroenterol Hepatol. 2019 Jan;17(1):139-147. doi: 10.1016/j.cgh.2018.07.009. Epub 2018 Sep 10.

18.

Methotrexate Is Not Superior to Placebo in Maintaining Steroid-Free Response or Remission in Ulcerative Colitis.

Herfarth H, Barnes EL, Valentine JF, Hanson J, Higgins PDR, Isaacs KL, Jackson S, Osterman MT, Anton K, Ivanova A, Long MD, Martin C, Sandler RS, Abraham B, Cross RK, Dryden G, Fischer M, Harlan W, Levy C, McCabe R, Polyak S, Saha S, Williams E, Yajnik V, Serrano J, Sands BE, Lewis JD; Clinical Research Alliance of the Crohn’s and Colitis Foundation.

Gastroenterology. 2018 Oct;155(4):1098-1108.e9. doi: 10.1053/j.gastro.2018.06.046. Epub 2018 Jun 30.

PMID:
29964043
19.

An Observational Cohort Study of Clostridium difficile Ribotype 027 and Recurrent Infection.

Rao K, Higgins PDR, Young VB.

mSphere. 2018 May 23;3(3). pii: e00033-18. doi: 10.1128/mSphere.00033-18. eCollection 2018 May-Jun.

20.

Correction: Corticosteroid Use and Complications in a US Inflammatory Bowel Disease Cohort.

Waljee AK, Wiitala WL, Govani S, Stidham R, Saini S, Hou J, Feagins LA, Khan N, Good CB, Vijan S, Higgins PDR.

PLoS One. 2018 May 9;13(5):e0197341. doi: 10.1371/journal.pone.0197341. eCollection 2018.

21.

Colorectal Cancer in Inflammatory Bowel Disease.

Stidham RW, Higgins PDR.

Clin Colon Rectal Surg. 2018 May;31(3):168-178. doi: 10.1055/s-0037-1602237. Epub 2018 Apr 1. Review.

22.

The IBD SGI Diagnostic Test Is Frequently Used by Non-gastroenterologists to Screen for Inflammatory Bowel Disease.

Berinstein JA, Waljee AK, Stidham RW, Higgins PDR, Govani SM.

Inflamm Bowel Dis. 2018 Apr 23;24(5):e18. doi: 10.1093/ibd/izy140. No abstract available.

PMID:
29688480
23.

Identifying intestinal fibrosis and inflammation by spectroscopic photoacoustic imaging: an animal study in vivo.

Zhu Y, Johnson LA, Huang Z, Rubin JM, Yuan J, Lei H, Ni J, Wang X, Higgins PDR, Xu G.

Biomed Opt Express. 2018 Mar 8;9(4):1590-1600. doi: 10.1364/BOE.9.001590. eCollection 2018 Apr 1.

24.

Predicting Corticosteroid-Free Biologic Remission with Vedolizumab in Crohn's Disease.

Waljee AK, Liu B, Sauder K, Zhu J, Govani SM, Stidham RW, Higgins PDR.

Inflamm Bowel Dis. 2018 May 18;24(6):1185-1192. doi: 10.1093/ibd/izy031.

25.

Systemic Inflammatory Responses in Ulcerative Colitis Patients and Clostridium difficile Infection.

Limsrivilai J, Rao K, Stidham RW, Govani SM, Waljee AK, Reinink A, Johnson L, Briggs E, Higgins PDR.

Dig Dis Sci. 2018 Jul;63(7):1801-1810. doi: 10.1007/s10620-018-5044-1. Epub 2018 Apr 12.

PMID:
29644517
26.

CT utilization abruptly increases at age 18 among patients with inflammatory bowel diseases in the hospital.

Govani SM, Higgins PDR, Rubenstein JH, Stidham RW, Waljee AK.

PLoS One. 2018 Mar 29;13(3):e0195022. doi: 10.1371/journal.pone.0195022. eCollection 2018.

27.

Predicting corticosteroid-free endoscopic remission with vedolizumab in ulcerative colitis.

Waljee AK, Liu B, Sauder K, Zhu J, Govani SM, Stidham RW, Higgins PDR.

Aliment Pharmacol Ther. 2018 Mar;47(6):763-772. doi: 10.1111/apt.14510. Epub 2018 Jan 22.

28.

Predicting Hospitalization and Outpatient Corticosteroid Use in Inflammatory Bowel Disease Patients Using Machine Learning.

Waljee AK, Lipson R, Wiitala WL, Zhang Y, Liu B, Zhu J, Wallace B, Govani SM, Stidham RW, Hayward R, Higgins PDR.

Inflamm Bowel Dis. 2017 Dec 19;24(1):45-53. doi: 10.1093/ibd/izx007.

29.

Defining an Optimal Adherence Threshold for Patients Taking Subcutaneous Anti-TNFs for Inflammatory Bowel Diseases.

Govani SM, Noureldin M, Higgins PDR, Heisler M, Saini SD, Stidham RW, Waljee JF, Waljee AK.

Am J Gastroenterol. 2018 Feb;113(2):276-282. doi: 10.1038/ajg.2017.438. Epub 2017 Dec 12.

30.

Developing a Standard Set of Patient-Centred Outcomes for Inflammatory Bowel Disease-an International, Cross-disciplinary Consensus.

Kim AH, Roberts C, Feagan BG, Banerjee R, Bemelman W, Bodger K, Derieppe M, Dignass A, Driscoll R, Fitzpatrick R, Gaarentstroom-Lunt J, Higgins PD, Kotze PG, Meissner J, O'Connor M, Ran ZH, Siegel CA, Terry H, van Deen WK, van der Woude CJ, Weaver A, Yang SK, Sands BE, Vermeire S, Travis SP.

J Crohns Colitis. 2018 Mar 28;12(4):408-418. doi: 10.1093/ecco-jcc/jjx161.

PMID:
29216349
31.

Assessing risk of fibrosis progression and liver-related clinical outcomes among patients with both early stage and advanced chronic hepatitis C.

Konerman MA, Lu D, Zhang Y, Thomson M, Zhu J, Verma A, Liu B, Talaat N, Balis U, Higgins PDR, Lok ASF, Waljee AK.

PLoS One. 2017 Nov 6;12(11):e0187344. doi: 10.1371/journal.pone.0187344. eCollection 2017.

32.

Differentiating Clostridium difficile Colitis from Clostridium difficile Colonization in Ulcerative Colitis: A Role for Procalcitonin.

Reinink AR, Limsrivilai J, Reutemann BA, Feierabend T, Briggs E, Rao K, Higgins PDR.

Digestion. 2017 Nov;96(4):207-212. doi: 10.1159/000481133. Epub 2017 Oct 14.

33.

Response to 'The end of the dosage of 6 Thioguanine nucleotides? Not so sure…'.

Waljee AK, Sauder K, Patel A, Segar S, Zhang Y, Zhu J, Stidham RW, Balis U, Higgins PDR.

J Crohns Colitis. 2018 Jan 5;12(1):127. doi: 10.1093/ecco-jcc/jjx134. No abstract available.

34.

External Validation of a Thiopurine Monitoring Algorithm on the SONIC Clinical Trial Dataset.

Waljee AK, Sauder K, Zhang Y, Zhu J, Higgins PDR.

Clin Gastroenterol Hepatol. 2018 Mar;16(3):449-451. doi: 10.1016/j.cgh.2017.08.021. Epub 2017 Aug 22. No abstract available.

35.

Endoscopic Balloon Dilation Size and Avoidance of Surgery in Stricturing Crohn's Disease.

Reutemann BA, Turkeltaub JA, Al-Hawary M, Waljee AK, Higgins PDR, Stidham RW.

Inflamm Bowel Dis. 2017 Oct;23(10):1803-1809. doi: 10.1097/MIB.0000000000001181.

36.

Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn's Disease: A Phase 2a Study.

Sands BE, Chen J, Feagan BG, Penney M, Rees WA, Danese S, Higgins PDR, Newbold P, Faggioni R, Patra K, Li J, Klekotka P, Morehouse C, Pulkstenis E, Drappa J, van der Merwe R, Gasser RA Jr.

Gastroenterology. 2017 Jul;153(1):77-86.e6. doi: 10.1053/j.gastro.2017.03.049. Epub 2017 Apr 5.

37.

Validation of a tool predicting important findings on computed tomography among Crohn's disease patients.

Govani SM, Waljee AK, Kocher KE, Swoger JM, Saul M, Higgins PD.

United European Gastroenterol J. 2017 Mar;5(2):270-275. doi: 10.1177/2050640616658218. Epub 2016 Jul 8. Review.

38.

Machine Learning Algorithms for Objective Remission and Clinical Outcomes with Thiopurines.

Waljee AK, Sauder K, Patel A, Segar S, Liu B, Zhang Y, Zhu J, Stidham RW, Balis U, Higgins PDR.

J Crohns Colitis. 2017 Jul 1;11(7):801-810. doi: 10.1093/ecco-jcc/jjx014.

39.

Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials.

Panés J, Sandborn WJ, Schreiber S, Sands BE, Vermeire S, D'Haens G, Panaccione R, Higgins PDR, Colombel JF, Feagan BG, Chan G, Moscariello M, Wang W, Niezychowski W, Marren A, Healey P, Maller E.

Gut. 2017 Jun;66(6):1049-1059. doi: 10.1136/gutjnl-2016-312735. Epub 2017 Feb 16.

40.

Measurement of Fibrosis in Crohn's Disease Strictures with Imaging and Blood Biomarkers to Inform Clinical Decisions.

Higgins PD.

Dig Dis. 2017;35(1-2):32-37. doi: 10.1159/000449080. Epub 2017 Feb 1. Review.

PMID:
28147365
41.

Serum Glycoproteome Profiles for Distinguishing Intestinal Fibrosis from Inflammation in Crohn's Disease.

Stidham RW, Wu J, Shi J, Lubman DM, Higgins PD.

PLoS One. 2017 Jan 23;12(1):e0170506. doi: 10.1371/journal.pone.0170506. eCollection 2017.

42.

Can Contrast-Enhanced Sonography Detect Bowel Wall Fibrosis in Mixed Inflammatory and Fibrotic Crohn Disease Lesions in an Animal Model?

Dillman JR, Rubin JM, Johnson LA, Moons DS, Higgins PD.

J Ultrasound Med. 2017 Mar;36(3):523-530. doi: 10.7863/ultra.16.04064. Epub 2017 Jan 10.

43.

Meta-Analytic Bayesian Model For Differentiating Intestinal Tuberculosis from Crohn's Disease.

Limsrivilai J, Shreiner AB, Pongpaibul A, Laohapand C, Boonanuwat R, Pausawasdi N, Pongprasobchai S, Manatsathit S, Higgins PD.

Am J Gastroenterol. 2017 Mar;112(3):415-427. doi: 10.1038/ajg.2016.529. Epub 2017 Jan 3. Review.

44.

Development and validation of the Ulcerative Colitis patient-reported outcomes signs and symptoms (UC-pro/SS) diary.

Higgins PDR, Harding G, Revicki DA, Globe G, Patrick DL, Fitzgerald K, Viswanathan H, Donelson SM, Ortmeier BG, Chen WH, Leidy NK, DeBusk K.

J Patient Rep Outcomes. 2017;2(1):26. doi: 10.1186/s41687-018-0049-2. Epub 2018 May 30.

45.

Development and validation of the Crohn's disease patient-reported outcomes signs and symptoms (CD-PRO/SS) diary.

Higgins PDR, Harding G, Leidy NK, DeBusk K, Patrick DL, Viswanathan HN, Fitzgerald K, Donelson SM, Cyrille M, Ortmeier BG, Wilson H, Revicki DA, Globe G.

J Patient Rep Outcomes. 2017;2(1):24. doi: 10.1186/s41687-018-0044-7. Epub 2018 May 9.

46.

Optimisation of Intestinal Fibrosis and Survival in the Mouse S. Typhimurium Model for Anti-fibrotic Drug Discovery and Preclinical Applications.

Johnson LA, Rodansky ES, Moons DS, Larsen SD, Neubig RR, Higgins PDR.

J Crohns Colitis. 2017 Jun 1;11(6):724-736. doi: 10.1093/ecco-jcc/jjw210.

47.

Functional Characterization of Inflammatory Bowel Disease-Associated Gut Dysbiosis in Gnotobiotic Mice.

Nagao-Kitamoto H, Shreiner AB, Gillilland MG 3rd, Kitamoto S, Ishii C, Hirayama A, Kuffa P, El-Zaatari M, Grasberger H, Seekatz AM, Higgins PD, Young VB, Fukuda S, Kao JY, Kamada N.

Cell Mol Gastroenterol Hepatol. 2016 Mar 3;2(4):468-481. eCollection 2016 Jul.

48.

Factors That Predict High Health Care Utilization and Costs for Patients With Inflammatory Bowel Diseases.

Limsrivilai J, Stidham RW, Govani SM, Waljee AK, Huang W, Higgins PD.

Clin Gastroenterol Hepatol. 2017 Mar;15(3):385-392.e2. doi: 10.1016/j.cgh.2016.09.012. Epub 2016 Sep 17.

49.

Investigator-Initiated IBD Trials in the United States: Facts, Obstacles, and Answers.

Herfarth HH, Jackson S, Schliebe BG, Martin C, Ivanova A, Anton K, Sandler RS, Long MD, Isaacs KL, Osterman MT, Sands BE, Higgins PD, Lewis JD.

Inflamm Bowel Dis. 2017 Jan;23(1):14-22. doi: 10.1097/MIB.0000000000000907. Review.

50.

Imaging of intestinal fibrosis: current challenges and future methods.

Stidham RW, Higgins PD.

United European Gastroenterol J. 2016 Aug;4(4):515-22. doi: 10.1177/2050640616636620. Epub 2016 Mar 2. Review.

Supplemental Content

Loading ...
Support Center